Official: L.A. County could hit COVID-19 herd immunity by end of July


If Los Angeles County continues to administer 400,000 COVID-19 vaccine shots a week, it will likely reach herd immunity among adults and older teenagers by mid- to late-July, Los Angeles County Public Health Director Barbara Ferrer said on Monday.
"The focus from here on in for us is to make it as easy as possible for eligible residents to get vaccinated," Ferrer told reporters during a news conference.
To reach herd immunity, a community must have enough people who have either been inoculated or have natural immunity to protect the rest of the population against the coronavirus. In Los Angeles County, more than 3 million people have received at least one dose of a COVID-19 vaccine, with 84 percent getting a second dose on schedule, 7 percent getting a second dose late, and 9 percent still waiting to get their second dose, the Los Angeles Times reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
If 2 million more get their first doses, 80 percent of all residents 16 and older will have received at least one shot. Ferrer stressed that for the county to reach herd immunity in mid- to late-July, vaccine rates must stay steady. There are 750 vaccination sites across Los Angeles County, and mobile vaccination teams are visiting communities where people have mobility issues or there is a lack of health care facilities.
California has recovered from the surge in cases over the fall and winter, with the state now seeing its lowest hospitalization rate since the beginning of the pandemic.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
Helsinki's year of zero road fatalities
Under the Radar Finland's 'Vision Zero' safety strategy 'shifts responsibility for crashes from road users to the designers of the road system'
-
Critics' choice: Outstanding new Japanese restaurants
Feature An all-women sushi team, a 15-seat listening bar, and more
-
Why do Dana White and Donald Trump keep pushing for a White House UFC match?
TODAY'S BIG QUESTION The president and the sports mogul each have their own reasons for wanting a White House spectacle
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts